Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOLVE: Aducanumab Safety in Asymptomatic ARIA
NCT03639987Phase 2Terminated
- Sponsor
- Biogen
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aducanumab in Alzheimer's disease (AD) (2 arms), sponsored by Biogen. Primary endpoint: Number of Participants With Clinically Impactful Amyloid-related Imaging Abnormalities (ARIA). Started Dec 2018; status: terminated.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03639987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639987.